Total (n = 220) | BRCA results known prior to surgery (n = 113) | BRCA results known after surgery (n = 107) | p-value | |
---|---|---|---|---|
Age at diagnosis | ||||
Mean age (years) | 47.3 | 45.7 | 49.1 | <0.05 |
Range (years) | 22.3 – 81.7 | 22.3 – 79.1 | 26.0 – 81.7 | |
Median age (years) | 46.4 | 44.0 | 47.6 | <0.05 |
Race | ||||
Caucasian | 189 (85.9%) | 97 (85.8%) | 92 (86.0%) | NS |
African American | 14 (6.4%) | 8 (7.1%) | 6 (5.6%) | NS |
Other | 3 (1.4%) | 2 (1.8%) | 1 (0.9%) | NS |
Unknown | 14 (6.4%) | 6 (5.3%) | 8 (7.5%) | NS |
Laterality | ||||
Unilateral | 208 (94.5%) | 106 (93.8%) | 10. (95.3%) | NS |
Bilateral | 12 (5.5%) | 7 (6.2%) | 5 (4.7%) | NS |
Histology | ||||
DCIS | 24 (10.9%) | 12 (10.6%) | 12 (11.2%) | NS |
IDC | 181 (82.3%) | 93 (82.3%) | 88 (82.2%) | NS |
ILC | 13 (5.9%) | 6 (5.3%) | 7 (6.5%) | NS |
Other | 2 (0.9%) | 2 (1.8%) | 0 (0.0%) | NS |
Grade | ||||
Grade 1 | 13 (5.9%) | 7 (6.2%) | 6 (5.6%) | NS |
Grade 2 | 58 (26.4%) | 35 (31.0%) | 23 (21.5%) | NS |
Grade 3 | 140 (63.6%) | 68 (60.2%) | 72 (67.3%) | NS |
Unknown | 9 (4.1%) | 3 (2.7%) | 6 (5.6%) | NS |
Tumor Size | ||||
Mean size (mm) | 27.02 | 30.80 | 22.95 | <0.05 |
Median size (mm) | 19.5 | 22.00 | 18.00 | <0.05 |
ER status | ||||
Negative | 104 (47.3%) | 51 (45.1%) | 53 (49.5%) | NS |
Positive | 113 (51.4%) | 62 (54.9%) | 51 (47.7%) | NS |
Unknown | 3 (1.4%) | 0 (0.0%) | 3 (2.8%) | NS |
PR status | ||||
Negative | 133 (60.5%) | 67 (59.3%) | 66 (61.7%) | NS |
Positive | 84 (38.2%) | 46 (40.7%) | 38 (35.5%) | NS |
Unknown | 3 (1.4%) | 0 (0.0%) | 3 (2.8%) | NS |
HER-2 Status | ||||
Negative | 158 (71.8%) | 89 (78.8%) | 69 (64.5%) | <0.05 |
Positive | 14 (6.4%) | 11 (9.7%) | 3 (2.8%) | <0.05 |
Not performed or unknown | 48 (21.8%) | 13 (11.5%) | 35 (32.7%) | <0.05 |
Triple negative breast cancer | ||||
Yes | 80 (36.4%) | 43 (38.1%) | 37 (34.6%) | NS |
No | 92 (41.8%) | 57 (50.4%) | 35 (32.7%) | <0.05 |
Unknown | 48 (21.8%) | 13 (11.5%) | 35 (32.7%) | <0.05 |
T- Stage | ||||
Tis | 24 (10.9%) | 12 (10.6%) | 12 (11.2%) | NS |
T1 | 101 (45.9%) | 46 (40.7%) | 55 (51.4%) | NS |
T2 | 66 (30.0%) | 38 (33.6%) | 28 (26.2%) | NS |
T3 | 23 (10.5%) | 12 (10.6%) | 11 (10.3%) | NS |
T4 | 6 (2.7%) | 5 (4.4%) | 1 (0.9%) | NS |
N-Stage | ||||
N0 | 133 (60.5%) | 67 (59.3%) | 66 (61.7%) | NS |
N1 | 69 (31.4%) | 32 (28.3%) | 37 (34.6%) | NS |
N2 | 15 (6.8%) | 12 (10.6%) | 3 (2.8%) | <0.05 |
N3 | 3 (1.4%) | 2 (1.8%) | 1 (0.9%) | NS |
Overall TNM Stage | ||||
Stage 0 (In-situ) | 24 (10.9%) | 12 (10.6%) | 12 (11.2%) | NS |
Stage I | 79 (35.9%) | 37 (32.7%) | 42 (39.3%) | NS |
Stage II | 83 (37.7%) | 42 (37.2%) | 41 (38.3%) | NS |
Stage III | 34 (15.5%) | 22 (19.5%) | 12 (112.2%) | NS |
Adjuvant radiation | ||||
Yes | 104 (47.3%) | 42 (37.2%) | 62 (57.9%) | <0.05 |
No | 116 (52.7%) | 71 (62.8%) | 45 (42.1%) | <0.05 |
Chemotherapy | ||||
None | 71 (32.3%) | 31 (27.4%) | 40 (37.4%) | NS |
Neoadjuvant chemotherapy | 49 (22.3%) | 43 (38.1%) | 6 (5.6%) | <0.05 |
Adjuvant chemotherapy | 100 (45.4%) | 39 (34.5%) | 61 (57.0%) | <0.05 |
BRCA1/2 results | ||||
BRCA1 mutation | 111 (50.5%) | 56 (49.6%) | 55 (51.4%) | NS |
BRCA2 mutation | 109 (49.5%) | 57 (50.4%) | 52 (48.6%) | NS |